3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Motor Activity
1
Lymphoma
1
Leukemia
1
Interventions
Rituximab
12
Biopsy
12
Specimen Handling
11
Cyclophosphamide
11
Magnetic Resonance Spectroscopy
10
obinutuzumab
7
Lenalidomide
7
fludarabine
6
Prednisone
6
pembrolizumab
5
Nuclear Medicine Department, Hospital
5
X-Rays
4
Doxorubicin
4
venetoclax
3
ibrutinib
3
glofitamab
3
fludarabine phosphate
3
acalabrutinib
3
Vincristine
3
Tacrolimus
3
Mycophenolic Acid
3
GSK2636771
3
Etoposide
3
Busulfan
3
Bendamustine Hydrochloride
3
zanubrutinib
2
trametinib
2
tocilizumab
2
palbociclib
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
Nadolol
×
30 days
×
Clear all
NCT06643221
2026-06-05
Allo-X
University of Arizona
Phase EARLY_PHASE1
Recruiting
200 enrolled